Be on top of World Pharma News
Want to place your News, Brand, Service, Product or Event in front of World Pharma News?
Contact us now.
Banner

Plasma-based treatment goes viral

Life-threatening viruses such as HIV, SARS, hepatitis and influenza, could soon be combatted in an unusual manner as researchers have demonstrated the effectiveness of plasma for inactivating and preventing the replication of adenoviruses.

When exposed to plasma - the fourth state of matter in addition to solids, liquids and gases - for a period of just 240 seconds, it was found that only one in a million viruses could still replicate - practically all were inactivated.

The study, published in IOP Publishing's Journal of Physics D: Applied Physics, is one of the first to concentrate specifically on viruses and builds on research that has already shown the usefulness of plasma in eradicating bacteria from skin and sterilising water.

Within a hospital environment, a plasma generating device could realistically rid hands of potentially lethal viruses that relay on a host organism to replicate and spread. In the long-term, plasma could be inhaled directly to treat viruses in the lungs, or applied to blood outside of the body to remove any viruses before transfusion.

The researchers, from the Max-Planck Institut für extraterrestrische Physik and Technische Universität München, specifically chose adenoviruses to examine as they are one of the most difficult viruses to inactivate. Illnesses resulting from this specific virus, for example, can only be managed by treating symptoms and complications of the infection, rather than targeting the actual virus itself.

Adenoviruses predominantly cause respiratory illnesses such as pneumonia and bronchitis and are hard to inactivate as the whole virus is encased in a protein layer, helping it to remain physically stable and tolerate moderate increases in heat and pH.

In this study, the adenoviruses were diluted to specific concentrations and then exposed to plasma for 240 seconds, before being incubated for an hour. A control group of adenoviruses were given the exact same treatment apart from the plasma exposure.

Two separate cell lines were then infected with the two sets of adenoviruses: the ones that were treated with plasma and the control group. To test whether a cell had the virus or not, the researchers programmed the virus to produce a protein that fluoresced green when a specific type of light was shone onto it.

Whilst the exact mechanisms behind the plasma's impressive effects are relatively unknown, it is thought that they are a result of a combination of reactions between the plasma and surrounding air, which create similar species to the ones found in our own immune system when under microbial attack.

The published version of the paper 'Effects of cold atmospheric plasmas on adenovirus in solution' (J L Zimmermann et al 2011 J. Phys. D: Appl. Phys. 44 505201) is freely available online from Wednesday 30 November at http://iopscience.iop.org/0022-3727/44/50/505201

World Pharma News RSS Channel
Subscribe to World Pharma News by Email

Follow/Join us on:   Facebook   Twitter   XING   LinkedIn   Google Groups    FeedBurner

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]

News in Pictures

http://www.worldpharmanews.com/components/com_gk3_photoslide/thumbs_big/9445461331.jpg

Abbott Launches New Psoriasisanswers.com Web site

August marks National Psoriasis Awareness Month, an opportunity to raise awareness about psoriasis, a skin disease that affects nearly 7.5 million Americans. For those living with this condition, finding information Read more

http://www.worldpharmanews.com/components/com_gk3_photoslide/thumbs_big/399322AstraZeneca_Headquarters.jpg

AstraZeneca Headquarters, London

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, Read more

http://www.worldpharmanews.com/components/com_gk3_photoslide/thumbs_big/280148roche_basel.jpg

Site Roche Basel

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in Read more

http://www.worldpharmanews.com/components/com_gk3_photoslide/thumbs_big/390839Gehry_Novartis.jpg

Gehry building, Novartis headquarters in Basel, Switzerland

Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving Read more

http://www.worldpharmanews.com/components/com_gk3_photoslide/thumbs_big/240209GSK_Corporate.jpg

GSK Corporate HQ

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better Read more

http://www.worldpharmanews.com/components/com_gk3_photoslide/thumbs_big/200324sanofi_avenits.jpg

Sanofi-aventis Group head office

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: Read more

http://www.worldpharmanews.com/components/com_gk3_photoslide/thumbs_big/964792Boehringer_Ingelheim_Center.jpg

Boehringer Ingelheim Center, Ingelheim, Germany

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 Read more

http://www.worldpharmanews.com/components/com_gk3_photoslide/thumbs_big/164840Novo_Nordisk.jpg

Novo Nordisk's corporate headquarters in Bagsværd, Denmark

Headquartered in Denmark, Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth Read more

Sponsored Video 

Be on top of World Pharma News
Want to place your News, Brand, Service, Product or Event in front of World Pharma News?
Contact us now.